Immunovia
0.819
SEK
-2.62 %
IMMNOV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
-2.62%
+34.04%
-3.65%
+14.81%
-6.96%
-6.01%
-97.78%
-98.66%
-94.02%
immunovia.com
Immunovia is a biotechnology company. The company's research and development is focused on molecular diagnostics, where the business focuses on driving the development and change of current working methods for diagnosing complex cancers and immune diseases. The vision is to establish blood-based tests to be able to identify different types of pancreatic cancer at an early stage. The company was founded in 2007 and is headquartered in Lund.
Revenue
1.58M
EBIT %
-18,763.29 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
IMMNOV
Daily low / high price
0.74 / 0.83
SEK
Market cap
138.99M SEK
Turnover
4.58M SEK
Volume
5.9M
Financial calendar
Annual report
25.02.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Försäkringsbolaget Avanza Pension | 11.6 % | 11.6 % |
| Vincent Saldell | 3.5 % | 3.5 % |
| Nordnet Pensionsförsäkring AB | 1.8 % | 1.8 % |
| Carl Borrebaeck | 1.1 % | 1.1 % |
| Jens Henrik Lensen | 1.0 % | 1.0 % |
| Simon Borsos | 1.0 % | 1.0 % |
| Vator Securities AB | 0.9 % | 0.9 % |
| Försäkringsaktiebolaget Skandia | 0.9 % | 0.9 % |
| Ghanem Georges Chouba | 0.8 % | 0.8 % |
| Sten Jonsson | 0.8 % | 0.8 % |
ShowingAll content types
Immunovia AB: Immunovia Publishes Interim Report for January-September 2024
Immunovia AB: Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas-Inherited Gastrointestinal Cancers
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools